Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALME: Erlotinib in Advanced NSCLC
NCT01320501Phase 4Suspended
- Sponsor
- Ministry of National Guard Health Affairs
- Start
- Oct 2009
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Ministry of National Guard Health Affairs. Primary endpoint: Pattern of use of TarcevaTM at 3 years. Started Oct 2009; status: suspended.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01320501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01320501.